Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1

Interventions

hypericin 4zanolimumab 3mogamulizumab 3cobomarsen 3Vorinostat 3Bexarotene 3denileukin diftitox 2Vitamin B 12 2Panobinostat 2Folic Acid 2Amines 2A-dmDT390-bisFv(UCHT1) protein 210-propargyl-10-deazaaminopterin 2talimogene laherparepvec 1resminostat 1ontuxizumab 1navitoclax 1forodesine 1TTI-621 1Radiation 1N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide 1Methotrexate 1Mechlorethamine 1MAC-ST-001 1Interleukin-12 Subunit p35 1Fentanyl 1Fenretinide 1Duration of Therapy 1Drug Therapy 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mycosis Fungoides × Interleukin-12 Subunit p35 × Clear all
NCT02542124 2018-11-16

NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)

Neumedicines Inc.

Phase 2 Unknown
10 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡